Gene Therapy for Rare Vision Loss Condition Granted Early Access in France

GenSight Biologics' LUMEVOQ® receives Compassionate Use Authorization to treat ND4-LHON, a severe form of Leber Hereditary Optic Neuropathy.

Apr. 11, 2026 at 1:04am

Got story updates? Submit your updates here. ›

A minimalist, neon-outlined illustration of a human eye, glowing against a dark background to conceptually represent the impact and promise of a gene therapy for a rare eye disease.A breakthrough gene therapy offers new hope for those affected by a devastating vision-robbing disease.Kansas City Today

Patients suffering from the devastating vision loss condition Leber Hereditary Optic Neuropathy (LHON) in France will soon have access to a groundbreaking gene therapy treatment. The French medicines agency ANSM has granted Compassionate Use Authorization for GenSight Biologics' LUMEVOQ®, a therapy designed to treat the ND4 mutation, the most common and severe form of LHON.

Why it matters

LHON is a rare, inherited mitochondrial disease that leads to rapid and irreversible vision loss, often resulting in legal blindness. The development of treatments like LUMEVOQ® is critical, as the ND4 mutation carries the worst prognosis among the leading LHON-causing genetic defects.

The details

The Compassionate Use Authorization, part of France's national AAC Program, allows patients with serious, rare, or disabling diseases to access treatments that haven't yet received marketing approval, provided there's a clear unmet medical need and no suitable alternative therapy. Eligible patients must meet specific criteria, including the duration since the onset of vision loss, to ensure the therapy is targeted to those who stand to benefit most.

  • The Compassionate Use Authorization for LUMEVOQ® was granted by the ANSM in April 2026.

The players

GenSight Biologics

A clinical-stage biopharma company at the forefront of developing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders.

ANSM

The French medicines agency that granted the Compassionate Use Authorization for LUMEVOQ®.

LHON

Leber Hereditary Optic Neuropathy, a rare, maternally inherited mitochondrial genetic disease that leads to rapid and typically irreversible vision loss.

ND4 mutation

The most prevalent cause of LHON, carrying the worst prognosis among the leading mutations.

LUMEVOQ® (lenadogene nolparvovec)

GenSight Biologics' gene therapy designed to treat ND4-LHON, the most common and severe form of LHON.

Got photos? Submit your photos here. ›

What’s next

The judge in the case will decide on Tuesday whether or not to allow Walker Reed Quinn out on bail.

The takeaway

This case highlights growing concerns in the community about repeat offenders released on bail, raising questions about bail reform, public safety on SF streets, and if any special laws to govern autonomous vehicles in residential and commercial areas.